Literature DB >> 29367708

Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.

Hanna Jean Khoury1, Amelia A Langston2, Vamsi K Kota2, Jennifer A Wilkinson2, Iskra Pusic3, Anand Jillella2, Stephanie Bauer3, Audrey S Kim2, Danielle Roberts2, Zaid Al-Kadhimi2, Imre Bodo2, Elliott Winton2, Martha Arellano2, John F DiPersio3.   

Abstract

Inhibition of the Janus-associated kinases (JAK) with ruxolitinib (RUX) reduces graft-versus-host disease (GVHD) in preclinical and clinical models. In total 19 allograft recipients with moderate/severe steroid-dependent chronic GVHD received RUX as ≥2nd line salvage. RUX was well tolerated, and led to complete/partial resolution of oral (92/7%), cutaneous (82/0%), hepatic (71/28%), gastro-intestinal (75/17%), musculoskeletal (33/67%), pulmonary (0/80%), scleroderma (0/75%), vaginal (0/75%), and ocular (0/100%) chronic GVHD. Overall 18 achieved partial response and 1 complete response according to NIH Consensus Criteria. Responses occurred early and were sustained which enabled discontinuation (68%) or reduction of steroids to physiologic doses (21%). We conclude that RUX is an effective steroid-sparing agent in chronic GVHD.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29367708      PMCID： PMC6041160          DOI： 10.1038/s41409-017-0081-5

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  13 in total

1.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Authors:  Madan H Jagasia; Hildegard T Greinix; Mukta Arora; Kirsten M Williams; Daniel Wolff; Edward W Cowen; Jeanne Palmer; Daniel Weisdorf; Nathaniel S Treister; Guang-Shing Cheng; Holly Kerr; Pamela Stratton; Rafael F Duarte; George B McDonald; Yoshihiro Inamoto; Afonso Vigorito; Sally Arai; Manuel B Datiles; David Jacobsohn; Theo Heller; Carrie L Kitko; Sandra A Mitchell; Paul J Martin; Howard Shulman; Roy S Wu; Corey S Cutler; Georgia B Vogelsang; Stephanie J Lee; Steven Z Pavletic; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-18       Impact factor: 5.742

2.  IFNγR signaling mediates alloreactive T-cell trafficking and GVHD.

Authors:  Jaebok Choi; Edward D Ziga; Julie Ritchey; Lynne Collins; Julie L Prior; Matthew L Cooper; David Piwnica-Worms; John F DiPersio
Journal:  Blood       Date:  2012-09-12       Impact factor: 22.113

3.  Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.

Authors:  Daniel Wolff; Michael Schleuning; Stephanie von Harsdorf; Ulrike Bacher; Armin Gerbitz; Michael Stadler; Francis Ayuk; Alexander Kiani; Rainer Schwerdtfeger; Georgia B Vogelsang; Guido Kobbe; Martin Gramatzki; Anita Lawitschka; Mohamad Mohty; Steven Z Pavletic; Hildegard Greinix; Ernst Holler
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-26       Impact factor: 5.742

Review 4.  Are we making progress in GVHD prophylaxis and treatment?

Authors:  Steven Z Pavletic; Daniel H Fowler
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

5.  Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.

Authors:  Stephanie J Lee; Daniel Wolff; Carrie Kitko; John Koreth; Yoshihiro Inamoto; Madan Jagasia; Joseph Pidala; Attilio Olivieri; Paul J Martin; Donna Przepiorka; Iskra Pusic; Fiona Dignan; Sandra A Mitchell; Anita Lawitschka; David Jacobsohn; Anne M Hall; Mary E D Flowers; Kirk R Schultz; Georgia Vogelsang; Steven Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-19       Impact factor: 5.742

6.  Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.

Authors:  Scott R Solomon; Connie A Sizemore; Michelle Ridgeway; Xu Zhang; Judith Smith; Stacey Brown; H Kent Holland; Lawrence E Morris; Asad Bashey
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-16       Impact factor: 5.742

7.  Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.

Authors:  Paul J Martin; Barry E Storer; Scott D Rowley; Mary E D Flowers; Stephanie J Lee; Paul A Carpenter; John R Wingard; Paul J Shaughnessy; Marcel P DeVetten; Madan Jagasia; Joseph W Fay; Koen van Besien; Vikas Gupta; Carrie Kitko; Laura J Johnston; Richard T Maziarz; Mukta Arora; Pamala A Jacobson; Daniel Weisdorf
Journal:  Blood       Date:  2009-03-06       Impact factor: 22.113

8.  Baricitinib in Patients with Refractory Rheumatoid Arthritis.

Authors:  Mark C Genovese; Joel Kremer; Omid Zamani; Charles Ludivico; Marek Krogulec; Li Xie; Scott D Beattie; Alisa E Koch; Tracy E Cardillo; Terence P Rooney; William L Macias; Stephanie de Bono; Douglas E Schlichting; Josef S Smolen
Journal:  N Engl J Med       Date:  2016-03-31       Impact factor: 91.245

Review 9.  Current issues in chronic graft-versus-host disease.

Authors:  Gérard Socié; Jerome Ritz
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

10.  Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.

Authors:  Jaebok Choi; Matthew L Cooper; Bader Alahmari; Julie Ritchey; Lynne Collins; Matthew Holt; John F DiPersio
Journal:  PLoS One       Date:  2014-10-07       Impact factor: 3.240
View more
  18 in total

1.  A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice.

Authors:  Asim Saha; Sharon Hyzy; Tahirih Lamothe; Katelyn Hammond; Nicholas Clark; Leanne Lanieri; Prashant Bhattarai; Rahul Palchaudhuri; Geoffrey O Gillard; Jennifer Proctor; Megan J Riddle; Angela Panoskaltsis-Mortari; Margaret L MacMillan; John E Wagner; Hans-Peter Kiem; Lisa M Olson; Bruce R Blazar
Journal:  Blood       Date:  2022-03-17       Impact factor: 22.113

2.  FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.

Authors:  Robert Q Le; Xin Wang; Hongfei Zhang; Hongshan Li; Donna Przepiorka; Jonathon Vallejo; Ruby Leong; Lian Ma; Kirsten B Goldberg; Richard Pazdur; Marc R Theoret; Angelo De Claro
Journal:  Oncologist       Date:  2022-06-08       Impact factor: 5.837

3.  Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide.

Authors:  Jiao-Yu Zhao; Si-Ning Liu; Lan-Ping Xu; Xiao-Hui Zhang; Yu Wang; Yu-Hong Chen; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Dong Mo
Journal:  Ann Hematol       Date:  2020-11-07       Impact factor: 3.673

4.  Ruxolitinib for steroid-refractory acute graft-versus-host disease.

Authors:  Wael Toama; Mark Fiala; Iskra Pusic; Peter Westervelt; John F Dipersio; Mark Schroeder
Journal:  Transpl Int       Date:  2019-12-13       Impact factor: 3.782

5.  Acute kidney injury after ruxolitinib: Common complication, uncommon cause.

Authors:  Samuel Strohbehn; Harish Seethapathy; Nifasha Rusibamayila; Ian Strohbehn; Meghan Lee; Gabriela Hobbs; Alla Keyzner; Kenar D Jhaveri; Meghan E Sise
Journal:  Am J Hematol       Date:  2020-04-17       Impact factor: 10.047

6.  Ruxolitinib treatment for bronchiolitis obliterans syndrome following hematopoietic stem cell transplant in a patient with primary hemophagocytic lymphohistiocytosis.

Authors:  Guang-Qiang Meng; Yi-Ni Wang; Jing-Shi Wang; Zhao Wang
Journal:  Chin Med J (Engl)       Date:  2021-01-05       Impact factor: 2.628

7.  Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease.

Authors:  Allison P Watson; Claudio G Brunstein; Shernan G Holtan
Journal:  Case Rep Transplant       Date:  2018-11-04

8.  Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD.

Authors:  Philip T Sobash; Achuta K Guddati; Vamsi Kota
Journal:  Case Rep Oncol Med       Date:  2020-04-06

9.  Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.

Authors:  Dong Wang; Yin Liu; Xiaoxuan Lai; Jia Chen; Qiao Cheng; Xiao Ma; Zhihong Lin; Depei Wu; Yang Xu
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

Review 10.  Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia.

Authors:  Jodi J Lipof; Kah Poh Loh; Kristen O'Dwyer; Jane L Liesveld
Journal:  Cancers (Basel)       Date:  2018-06-04       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.